Market research
IGX.V IntelGenx Technologies Corp
V CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 90M
- P/E ratio
- Not available
- Analyst target
- 0.99
- Dividend yield
- 0.0%
- Beta
- 2.56
Profile
Company facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US45822R1014
- Market cap
- 90M
- P/E ratio
- Not available
- Analyst target
- 0.99
- Dividend yield
- 0.0%
- Beta
- 2.56
About
About IntelGenx Technologies Corp
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IGX.V discussion.
5 years, 5 months ago
IntelGenx Technologies Corp is currently in a long term uptrend where the price is trading 38.7% above its 200 day moving average.
From a valuation standpoint, the stock is 96.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 34.1.
IntelGenx Technologies Corp's total revenue rose by 1061.8% to $790K since the same quarter in the previous year.
Its net income has increased by 52.0% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 76.0% to $-533K since the same quarter in the previous year.
Based on the above factors, IntelGenx Technologies Corp gets an overall score of 5/5.